tirzepatide death Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring Eli Lilly sues companies selling

Zepbound carries a boxed warning regarding the risk of thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

report palpitations or persistent tachycardia [1] [11] Additional monitoring considerations: If you have diabetic retinopathy, follow appropriate ophthalmology care as recommended by the ADA If using tirzepatide for weight management, use non-oral contraception or backup contraceptive methods for 4 weeks after initiation and after each dose increase Contact your healthcare provider immediately if pregnancy occurs or is planned, as tirzepatide for weight management is not recommended during pregnancy Clinical follow-up schedule: Expect appointments at 4 weeks (first dose escalation), 812 weeks (metabolic assessment), and then every 3 months during the first year

Samples showed significant shortfalls compared to their labeled amounts

The platforms that answer these questions transparently tend to be the ones that deserve further consideration